Pharma
OIS Retina, set to kick off next Friday, July 20, when the annual meeting of the American Society of Retina Specialists (ASRS) starts in Vancouver,…
Read More
Developers of FYB201 may be getting a leg up in the race for a Lucentis biosimilar with the publication of interim results that confirm the…
Read More
Shire plc’s decision last week to accept the $62 billion acquisition offer by Takeda Pharmaceutical Company Ltd. has fed speculation in the pharma trade press…
Read More
WASHINGTON, DC – Having OIS@ASCRS 2018 here provided the perfect opportunity for representatives of the US Food and Drug Administration to impart wisdom on how…
Read More
Here are 15 takeaways from last week’s OIS@ASCRS 2018. Barry Cheskin of PowerVision reported on a pilot study of 27 patients who had the FluidVision…
Read More
There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…
Read More
Over the past decade, the treatment of ocular surface conditions such as dry eye and meibomian gland dysfunction (MGD) has evolved from “pats on the…
Read More
Apellis Pharmaceuticals‘ plans to begin the Phase III trial of its complement C3 inhibitor candidate APL-2 for treatment of geographic atrophy received a boost last…
Read More
Clinical Trial Updates Due at Angiogenesis Meeting Investigators will present a host of updates on clinical trials in retina at Angiogenesis, Exudation and Degeneration 2018…
Read More
At the 36th annual JP Morgan Healthcare Conference in San Francisco, Allergan CEO Brent Saunders said a disconnect exists between the company’s 2017 results and…
Read More
As House and Senate negotiators reportedly reached agreement on a tax-reform package, the fate of the orphan drug tax credit remained uncertain. Advocates have been…
Read More
The forces driving ophthalmic innovation are digitization and demographics, namely in the emergence of millennials, and how the major players in ophthalmology respond to those…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")